Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens.
Intracerebral murine glioma 26 was used as a model system for evaluating two-drug combinations of antitumor agents, BCNU was combined with either procarbazine, dianhydrogalactitol, or ellipticine. CCNU was combined with procarbazine. All combinations were more active than the individual drugs alone. The most potent combinations achieved 85-100% tumor "cure" at 120 days, with combined toxicity indices of 0.25 (CCNU-procarbazine) to 1.30 (NCNU-dianhydrogalactitol). The experimental data were compared to clinical studies with CCNU, procarbazine, and vincristine, and BCNU-procarbazine.
D000818:Animals; D002330:Carmustine / Q000627:therapeutic use; D003961:Dianhydrogalactitol / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004611:Ellipticines / Q000627:therapeutic use; D005910:Glioma / Q000188:drug therapy*; D008130:Lomustine / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011344:Procarbazine / Q000627:therapeutic use; D013997:Time Factors; D014184:Transplantation, Homologous
D004611:Ellipticines; D011344:Procarbazine; D003961:Dianhydrogalactitol; D008130:Lomustine; D002330:Carmustine